Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Interest Expenses (2022 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Interest Expenses for 4 consecutive years, with $4.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest Expenses fell 15.27% to $4.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.6 million, a 0.1% change, with the full-year FY2025 number at $20.6 million, changed 0.1% from a year prior.
  • Interest Expenses was $4.6 million for Q4 2025 at Rhythm Pharmaceuticals, down from $4.7 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $5.8 million in Q2 2025 to a low of $2.1 million in Q3 2022.
  • A 4-year average of $4.3 million and a median of $4.6 million in 2024 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: skyrocketed 84.12% in 2024, then dropped 18.21% in 2025.
  • Rhythm Pharmaceuticals' Interest Expenses stood at $3.0 million in 2022, then soared by 51.11% to $4.6 million in 2023, then rose by 19.71% to $5.4 million in 2024, then fell by 15.27% to $4.6 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Interest Expenses are $4.6 million (Q4 2025), $4.7 million (Q3 2025), and $5.8 million (Q2 2025).